Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Asset Writedowns and Impairment (2018 - 2025)

Historic Asset Writedowns and Impairment for Aytu Biopharma (AYTU) over the last 6 years, with Q4 2025 value amounting to $800000.0.

  • Aytu Biopharma's Asset Writedowns and Impairment rose 70000.0% to $800000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $9.3 million, marking a year-over-year increase of 57367.27%. This contributed to the annual value of $8.3 million for FY2025, which is 58858.33% up from last year.
  • Per Aytu Biopharma's latest filing, its Asset Writedowns and Impairment stood at $800000.0 for Q4 2025, which was up 70000.0% from $300000.0 recorded in Q3 2025.
  • Aytu Biopharma's 5-year Asset Writedowns and Impairment high stood at $45.2 million for Q1 2022, and its period low was $100000.0 during Q4 2021.
  • For the 5-year period, Aytu Biopharma's Asset Writedowns and Impairment averaged around $5.2 million, with its median value being $550000.0 (2025).
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first skyrocketed by 1935300.0% in 2021, then crashed by 9977.87% in 2023.
  • Over the past 5 years, Aytu Biopharma's Asset Writedowns and Impairment (Quarter) stood at $100000.0 in 2021, then surged by 2500.0% to $2.6 million in 2022, then crashed by 96.15% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then soared by 700.0% to $800000.0 in 2025.
  • Its last three reported values are $800000.0 in Q4 2025, $300000.0 for Q3 2025, and $8.1 million during Q2 2025.